soul trial oral semaglutide cardiovascular outcomes trial results SELECT Researchers to present CV findings

GLP-1 stands for glucagon-like peptide-1, a hormone that plays a major role in managing your blood sugar and appetite

How It Compares to Other Treatments To comprehend the advancement in this therapy, it is first useful to provide a point of reference with other similar drugs in this category: Semaglutide (Ozempic, Wegovy): GLP-1 Target Average weight loss: ~15% Tirzepatide (Mounjaro): GLP-1 + GIP Targets Average weight loss: ~20% to 22% Retatrutide: GLP-1 + GIP + Glucagon Targets Average weight loss of 24% in clinical trials As a result, triple-agonist therapy can be an extremely promising new option for medically induced weight loss

This is a must in my daily wellness routine

Patients with higher baseline insulin resistance or persistent metabolic dysfunction may benefit from more intensive monitoring and structured intervention during discontinuation